Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 361 to 375 of 539 results for syndrome

  1. Stapled transanal rectal resection for obstructed defaecation syndrome (IPG169)

    This guidance has been updated and replaced by NICE HealthTech guidance 224.

  2. Arthroscopic femoro-acetabular surgery for hip impingement syndrome (IPG213)

    This guidance has been updated and replaced by NICE HealthTech guidance 273.

  3. Open femoro-acetabular surgery for hip impingement syndrome (IPG203)

    This guidance has been updated and replaced by NICE HealthTech guidance 270.

  4. Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)

    We have moved interventional procedures guidance 709 to become HealthTech guidance 596. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  5. Phrenic nerve pacing for congenital central hypoventilation syndrome (IPG790)

    We have moved interventional procedures guidance 790 to become HealthTech guidance 725. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  6. Axonics sacral neuromodulation system for faecal incontinence (MIB259)

    NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .

  7. Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)

    NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .

  8. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued Reference number: GID-TA10767

  9. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  10. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (IPG362)

    Interventional procedures, IPG362 - Issued: October 2010 --> We have moved interventional procedures guidance 362 to become HealthTech guidance 235. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  11. The effectiveness of pulsatile gonadotrophin-releasing hormone in women with clomifene citrate-resistant polycystic ovary syndrome is uncertain and is therefore not recommended outside a research context. [2004]

    ing hormone in women with clomifene citrate-resistant polycystic ovary syndrome is uncertain and is therefore not recommended outside a...

  12. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  13. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.